The University of Utah is recognized as a Top-Tier 1 research university by the Carnegie Classification of Institutions in Higher Education. According to the Vice President of Research the University was awarded 2,326 grants in 2018 and had $515 million in research funding. According to the National Institutes of Health, the university received $152,843,112 from them this year.Read More
Science Market Update
The NIH awarded $11.5 million grant to The University of Utah to Study Sarcomagenesis.Read More
If you sell laboratory products that can help life science researchers in Utah, join Biotechnology Calendar on August 30, 2017 as we introduce Utah researchers to the best lab products & services currently available at the upcoming BioResearch Product Faire™ Event at the University of Utah on 8/30/17.Read More
Last year in a blog of ours on the future of genome sequencing we referenced a July appeals court ruling that protected Utah's Myriad Genetics' patent on two genes known to be indicators of breast cancer risk. Now, in a recent Supreme Court ruling on that same case, the previous ruling has been overturned and the case returned to the lower court for rehearing. This decision follows another important high court ruling on the patentability of genes: Mayo vs. Prometheus Labs (San Diego), which also just ruled against a company's right to hold patents on human genes, and which was quoted as a precedent in the latest Myriad judgement.
Research by the University of Utah and Omica, Inc. reveal a new computational biology software tool that could dramatically change the way genetic diseases are detected. Published in Genome Research, the Variant Annotation, Analysis and Selection Tool (VAAST) can identify disease causing mutations in individual human genomes.